4 Therapies|Clear filters
Reg. name: Dacogen
Class: Hypomethylating agent
It has been demonstrated that decitabine (Dacogen®) can cause DNA demethylation by inactivation of DNA Methyltransferase-1 (DNMT-1), the enzyme responsible for methylation of the DNA. The inhibition of this enzyme leads to in-gene promoter hypomethylation that can result in reactivation of tumour suppressor genes, inducing cellular differentiation or cellular senescence followed by programmed cell death.
- Dacogen® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/27127. [Accessed January 2017].
DACOGEN® is indicated for the treatment of adult patients with newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy
Reg. name: Rydapt®
Class: Multi-targeted Tyrosine Kinase Inhibitor (TKI)
RYDAPT® is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive